1. Home
  2. BPTH vs SGN Comparison

BPTH vs SGN Comparison

Compare BPTH & SGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPTH
  • SGN
  • Stock Information
  • Founded
  • BPTH 2007
  • SGN 2019
  • Country
  • BPTH United States
  • SGN United States
  • Employees
  • BPTH N/A
  • SGN N/A
  • Industry
  • BPTH Biotechnology: Pharmaceutical Preparations
  • SGN
  • Sector
  • BPTH Health Care
  • SGN
  • Exchange
  • BPTH Nasdaq
  • SGN Nasdaq
  • Market Cap
  • BPTH 4.0M
  • SGN 4.1M
  • IPO Year
  • BPTH N/A
  • SGN 2023
  • Fundamental
  • Price
  • BPTH $0.82
  • SGN $6.92
  • Analyst Decision
  • BPTH Strong Buy
  • SGN
  • Analyst Count
  • BPTH 2
  • SGN 0
  • Target Price
  • BPTH $30.00
  • SGN N/A
  • AVG Volume (30 Days)
  • BPTH 107.7K
  • SGN 111.3K
  • Earning Date
  • BPTH 11-15-2024
  • SGN 12-03-2024
  • Dividend Yield
  • BPTH N/A
  • SGN N/A
  • EPS Growth
  • BPTH N/A
  • SGN N/A
  • EPS
  • BPTH N/A
  • SGN N/A
  • Revenue
  • BPTH N/A
  • SGN $576,488.00
  • Revenue This Year
  • BPTH N/A
  • SGN N/A
  • Revenue Next Year
  • BPTH N/A
  • SGN N/A
  • P/E Ratio
  • BPTH N/A
  • SGN N/A
  • Revenue Growth
  • BPTH N/A
  • SGN 147.76
  • 52 Week Low
  • BPTH $0.61
  • SGN $5.42
  • 52 Week High
  • BPTH $12.40
  • SGN $105.07
  • Technical
  • Relative Strength Index (RSI)
  • BPTH 40.36
  • SGN 38.67
  • Support Level
  • BPTH $0.74
  • SGN $6.00
  • Resistance Level
  • BPTH $0.85
  • SGN $13.73
  • Average True Range (ATR)
  • BPTH 0.09
  • SGN 1.72
  • MACD
  • BPTH -0.01
  • SGN -0.33
  • Stochastic Oscillator
  • BPTH 53.85
  • SGN 14.11

About BPTH Bio-Path Holdings Inc.

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

About SGN Signing Day Sports Inc.

Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.

Share on Social Networks: